The initial results of MRI-TRUS fusion prostate biopsy in high volume tertiary center

FIGURE 1.

FIGURE 2.

Comparison of time-based patient groups for learning curve estimation on institution level

	Targeted BX			Systematic BX			Overall BX
	Pearson χ2	df	sig	Pearson χ2	df	sig	Pearson χ2	df	sig
2 patient groups	0.458	1	0.498	0.658	1	0.417	0.291	1	0.590
3 patient groups	2.145	2	0.342	2.265	2	0.322	1.373	2	0.503
6 patient groups	4.807	5	0.440	2.872	5	0.720	2.322	5	0.803

Patient and lesion characteristics

	min	max	mean ± SD	median
Age (years)	35	91	69.0 ± 7.9	70.0
*Total PSA concentration (ng/mL)	0.45	115.4	9.7 ± 11.7	7.0
Prostate volume (ml)	15	313	52.8 ± 32.3	45
No. lesions biopsied in a patient	1	3	1.4 ± 0.6	1.0
Largest diameter of lesion (mm)	3.0	41.0	12.8 ± 6.6	11.5
No. of cores per lesion targeted BX	1	8	4.26 ± 1.2	4.0
No. of cores systematic BX	0	14	6.9 ± 1.8	6.0
No. of MRI-TRUS fusion targeted BX performed by urologist before	1	65	22.5 ± 19.7	20.0

Proportion of positive targeted biopsy (BX) lesions categorised by Prostate Imaging-Reporting and Data System (PIRADS) score

	Negative BX	Positive BX	Total
PIRADS 3 (%)	104 (81.9%)	23 (18.1%)	127
PIRADS 4 (%)	108 (52.9%)	96 (47.1%)	204
PIRADS 5 (%)	13 (16.0%)	68 (84.0%)	81

Results of multiple logistic regression of positive histopathologic result

	Sig	Odds ratio	95% C.I. for odds ratio
			Lower	Upper
Max lesion diameter	0.945	0.998	0.955	1.044
Prostate volume	< 0.001	0.978	0.968	0.988
*Total PSA concentration	0.050	1.050	1.000	1.103
PIRADS 3	< 0.001
PIRADS 4	< 0.001	3.208	1.848	5.567
PIRADS 5	< 0.001	16.222	6.475	40.645
Number of cores per lesion	0.034	1.238	1.016	1.508
Number of previous patients with targeted BX performed by urologist	0.113	1.013	0.997	1.028